1. Advanced NSCLC Without Actionable Mutations

2. Discussion of Off-Label Use and Investigational Agents

3. Introduction

4. Evolution of NSCLC Subtyping From Histologic to Molecular Based

5. First-Line Treatment Considerations

6. Guidelines for Molecular Profiling and Treatment Decisions

7. Guidelines for Molecular Profiling and Treatment Decisions (cont)

8. Survival by Use of Targeted Therapy

9. Standard of Care for Patients Without Identifiable Driver Mutations

10. Phase 3 Trial: CP vs CG in Advanced NSCLC

11. PointBreak Study Design

12. PointBreak Efficacy Results

13. Maintenance Therapy

14. Maintenance Therapy (cont)

15. ECOG 5508: Maintenance Therapy Trial in Advanced NSCLC

16. Squamous NSCLC: An Unmet Treatment Need

17. Phase 3 Study Design

19. SQUIRE: Study Design

20. SQUIRE: Results

21. REVEL: Study Design

22. REVEL: Results

25. Phase 3 OAK Trial: Atezolizumab vs Docetaxel in Previously Treated NSCLC

26. Phase 3 OAK Trial: Preliminary Results Presented at ESMO 2016

27. Pembrolizumab

28. Keynote-024: Phase 3 Trial of Frontline Pembrolizumab

29. CheckMate-026: Nivolumab in Frontline Therapy

30. Immune-Related AEs Associated With Immune Checkpoint Inhibitors

31. Summary of PD-1/PD-L1 Blockade Immune-Mediated AEs

32. Conclusions

33. Abbreviations

34. Abbreviations (cont)